(IN BRIEF) A major data-driven study from Aalborg University has found that missing periods of continuous glucose monitor use in people with diabetes are closely linked to poorer blood sugar control — and likely not random. Analyzing sensor data from … Read the full press release
Posted in Business, Denmark, Education, Healthcare, News, Science, Society, Technology
Tagged Aalborg University, blood sugar control, CGM sensors, continuous glucose monitoring, Denmark diabetes statistics, diabetes research, Diabetes Technology & Therapeutics, digital health tools, glycemic regulation, missing data impact, Morten Hasselstrøm Jensen, New Insights: Gaps in Glucose Monitoring May Mask Treatment Failures in Diabetes Patients, Novo Nordisk, patient engagement, personalized diabetes care, real-world evidence, sensor usage patterns, Simon Lebech Cichosz, Steno Diabetes Center North Jutland, type 1 diabetes, type 2 diabetes
(IN BRIEF) A team of researchers from the University of Copenhagen has revealed groundbreaking findings about insulin resistance, showing that it varies widely on a molecular level even among healthy individuals and those diagnosed with type 2 diabetes. This discovery … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged Anna Krook, Atul Deshmukh, diabetes research, early diagnosis, insulin resistance, Jeppe Kjærgaard Northcote, Karolinska Institutet, molecular signatures, muscle tissue, personalized treatments, precision medicine, proteomics, Steno Diabetes Center, type 2 diabetes, University of Copenhagen
(IN BRIEF) A team at the Technical University of Munich has developed synthetic macrocyclic peptides that inhibit harmful protein aggregation linked to Parkinson’s disease. The peptides also block the interactions between proteins involved in Alzheimer’s and type 2 diabetes, which … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged Alzheimer’s disease, amyloid plaques, Aphrodite Kapurniotu, biomedicine research, cross-seeding inhibition, DFG, EPFL, German Research Foundation, Helmholtz Center Munich, LMU University Hospital, macrocyclic peptides, metabolic disorders, multifunctional drugs, neurodegenerative diseases, Parkinson's disease, peptide biochemistry, protein aggregation, SFB 1035, synthetic peptides, Technical University of Munich, TUM, type 2 diabetes
(IN BRIEF) Diavantis, a Dutch company focused on supporting individuals with type 2 diabetes, has been awarded an EFRO grant to develop an innovative app aimed at guiding patients toward a medication-free life. The project, which leverages AI and IoT … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, Netherlands, News, Science, Technology
Tagged AI, diabetes management, Diavantis, EFRO Subsidy, Elisabeth Wilhelm, health technology, Healthcare Innovation, IoT, Lifestyle Intervention, Medication-Free Life, mobile app, partnership, type 2 diabetes, University of Groningen
(IN BRIEF) A study by the Technical University of Munich (TUM), LMU Hospital Munich, and Helmholtz Munich found that while intermittent fasting benefits adult mice by improving insulin sensitivity, it harms beta cell development in adolescent mice, which could have … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged adolescent mice, adolescents, Alexander Bartelt, beta cell function, Cell Reports, cellular development, diabetes treatment, dietary practices, Health Risks, Helmholtz Munich, insulin sensitivity, insulin-producing beta cells, intermittent fasting, LMU Hospital Munich, metabolic health, METABOLISM, single-cell sequencing, Stephan Herzig, Technical University of Munich, teenage health, TUM, type 1 diabetes, type 2 diabetes
(IN BRIEF) AstraZeneca and Eccogene have signed an exclusive license agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) designed for the treatment of obesity, type-2 diabetes, and other cardiometabolic conditions. Initial results from the Phase … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Adrian Kemp, AstraZeneca, Cardiometabolic Conditions, ECC5004, Eccogene, Exclusive License, Jingye Zhou, Obesity, Oral GLP-1RA, partnership, Sharon Barr, sustainability, type 2 diabetes
(IN BRIEF) New research from the University of East Anglia has found that being vaccinated against Covid-19 can halve the risk of developing long Covid. The study, which is the largest of its kind and includes more than 860,000 patients, … Read the full press release
Posted in Education, Healthcare, Management, Media, News, Science, United Kingdom
Tagged anxiety, asthma, comorbidities, COPD, coronary heart disease, depression, Dr Eleana Ntatsaki, hospitalisation, immunosuppression, long Covid, overweight, Prof Vassilios Vassiliou, risk factors, smokers, study, type 2 diabetes, University of East Anglia, vaccinated, WOMEN
(PRESS RELEASE) PARIS, 12-Apr-2022 — /EuropaWire/ — Diabeloop, a pioneer in the field of therapeutic artificial intelligence, leverages the potential of its diabetes technology to enable the integration of insulin pens into its hybrid closed-loop system using a unique app. … Read the full press release
Posted in Denmark, France, Healthcare, News, Pharma & Biotech, Spain, Technology
Tagged aid, automated insulin delivery, BIOCORP, DBL-4pen, DBL-hu, DBLG1, Diabeloop, Diabetes, Erik Huneker, insulin pen, insulin therapy, Mallya®, Marc Julien, multiple daily insulin injections, Prof. Hélène Hanaire, Seagrove Partners, Simon-Kucher, smart pen, Stéphanie JEGU, therapeutic AI, type 1 diabetes, type 2 diabetes, University Hospital of Toulouse, YourLoops
Scientists are closer to understanding the genetic causes of type 2 diabetes by identifying 111 new chromosome locations (‘loci’) on the human genome that indicate susceptibility to the disease, according to a UCL-led study in collaboration with Imperial College London. … Read the full press release
Posted in Education, Healthcare, Science, United Kingdom
Tagged Dr Nikolas Maniatis, Dr Toby Andrew, genetic causes of type 2 diabetes, type 2 diabetes, UCL
NOTTINGHAM, 04-Oct-2016 — /EuropaWire/ — Failure to assess people’s language skills when recruiting patients to clinical trials for diabetes treatments may be leading to black, Asian and ethnic minority (BAME) patients being underrepresented or excluded, says a new study. BAME patients … Read the full press release
STOCKHOLM, 27-Sep-2016 — /EuropaWire/ — New understanding of how hormone-producing cells in the pancreas decode their genetic instructions is pointing to novel targets for next generation medicines for type 2 diabetes, obesity and other metabolic disorders. A large scale analysis of … Read the full press release
Leicestershire, UK, 20-Sep-2016 — /EuropaWire/ — A new drive to raise awareness of Type 2 diabetes in ethnic minority communities in Leicestershire has been launched. A six-month programme of activities, including dancing sessions and healthy eating workshops, has started in a … Read the full press release
LIVERPOOL, 12-11-2015 — /EuropaWire/ — Researchers from the University of Liverpool, working with colleagues from Oxford and international partners, have improved the understanding of the processes that can lead to the development of type 2 diabetes. The research, published in Nature Genetics, shows … Read the full press release
Posted in Education, Healthcare, Science, United Kingdom
Tagged DNA sequence, Nature Genetics, Professor Mark McCarthy, type 2 diabetes, University of Liverpool
LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone PARIS, 14-9-2015 — /EuropaWire/ — Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with … Read the full press release
Posted in France, Healthcare, Pharma & Biotech, Science
Tagged glargine, insulin, LixiLan-L Phase III clinical trial, metformi, Sanofi, type 2 diabetes
Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 … Read the full press release
Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks Ingelheim, Germany and Indianapolis, US, 8-6-2015 — /EuropaWire/ — A Phase III clinical trial has … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged blood glucose, Boehringer Ingelheim, empagliflozin, metformin, Professor Hans-J. Woerle, type 2 diabetes
People with type 2 diabetes are physically less able to recover from stress, finds a study by scientists at UCL and the University of Zurich, funded by the British Heart Foundation. LONDON, 22-10-2014 — /EuropaWire/ — These findings could lead … Read the full press release
Posted in Education, Healthcare, United Kingdom
Tagged Dr Sanjay Thakrar, Professor Andrew Steptoe, stress, the University of Zurich, type 2 diabetes, UCL
London, UK, 15-1-2014 — /EuropaWire/ — AstraZeneca and Bristol-Myers Squibb Company announced the US Food and Drug Administration (FDA) approved FARXIGA™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with … Read the full press release
2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release
Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science
Tagged 73rd Scientific Sessions®, American Diabetes Association, Boehringer Ingelheim, Diabetes, dipeptidyl peptidase-4, DPP-4, Dr. Odd Erik Johansen, Eli Lilly, Germany, Indianapolis, Ingelheim, Linagliptin, T2D, type 2 diabetes, US
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?